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EFFECT OF TREATMENT WITH A NRF2 ACTIVATOR ON IN VIVO PROTEOSTASIS 
IN MICE 
 
Aging is characterized by progressive declines in cellular function, often resulting from 
oxidative stress. Redox homeostasis is perturbed when the production of reactive 
oxygen species (ROS) exceeds the capacity of antioxidant defenses to eliminate ROS. 
Chronic imbalances in ROS production and clearance can lead to disruptions in 
proteostasis by causing unrepairable damage to proteins. Nuclear factor erythroid-
derived 2-like 2 (Nrf2) exerts transcriptional regulation over endogenous antioxidant 
defenses by regulating the transcription of antioxidant enzymes and a myriad of 
cytoprotective proteins. Nrf2 activation has received attention as a therapeutic 
intervention to preserve cellular function. Our lab has characterized the treatment 
effects of Protandim and PB125, phytochemical compounds known to activate Nrf2. The 
collective findings from our group using both in vitro and in vivo experiments suggest 
that both compounds are effective for improving proteostasis; however, compared to 
Protandim, PB125 is more efficacious for sustained Nrf2 activation due to its ability to 
inhibit mechanisms of the Nrf2 shutdown pathway. We speculate that PB125 may have 
additional benefits on mechanism of proteostasis in vivo; thus, the purpose of the 
present study was to examine the effects of two doses of PB125 supplementation on 
proteostasis. We randomly assigned 51 male C57BL6/J mice aged 15-16 months to 




n=18/group during a 5-week feeding study. Mice were isotopically labeled with 8% 
deuterium oxide (D2O) administered in the drinking water to simultaneously measure 
protein and DNA synthesis rates in mitochondrial (mito), cytosolic (cyto), and mixed 
(mixed) subcellular fractions of heart, liver, and skeletal muscle tissues. We 
hypothesized that mice treated with PB125 would have enhanced proteostasis 
outcomes; however, our results indicate that PB125 supplementation did not affect 
mechanisms of proteostasis. No significant differences were found in protein or DNA 
synthesis rates between treatment groups, and our secondary measures further support 
that PB125 did not affect the proteostatic network, as there were no significant 
differences observed in Nrf2-regulated protein expression or protein aggregation. From 
our data we were able to confirm that oral administration of PB125 is safe; however, 
further in vivo investigations are warranted in order to confirm the role of PB125 in 
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CHAPTER I: INTRODUCTION 
I. Aging 
 
Aging is the progressive decline in physiological function across the lifespan of an 
organism, which, at least in part, is attributable to accumulation of damage to proteins, 
lipids, and DNA (Richardson and Schadt 2014). Damage sustained to cellular structures 
over time is a consequence of chronic inflammation and excessive production of ROS 
(Murali and Panneerselvam 2007). ROS are inevitable by-products of life-sustaining 
metabolic processes (Richter-Dennerlein, Oeljeklaus et al. 2016). However, 
endogenous production of ROS becomes elevated with aging, effectively overwhelming 
the capacity of antioxidant defenses to maintain redox homeostasis (Seals, Jablonski et 
al. 2011). Accordingly, the aging phenotype is associated with high exposures to 
oxidative stress with consequent disruptions in proteostasis, or the maintenance of 
protein homeostasis (Klaips, Jayaraj et al. 2018). Moreover, a diminished capacity to 
maintain proteostasis induced by oxidative stress is central to the etiology of several 
age-related pathologies, including cardiovascular disease (McLendon and Robbins 
2015), liver cirrhosis (Dasarathy and Hatzoglou 2018), and sarcopenia (Meng and Yu 
2010). 
 
Activation of the transcription factor Nrf2 induces the transcription of an array of genes 
encoding cytoprotective proteins that provide resistance to oxidative stress and 
inflammation, and promote maintenance of protein turnover (Nguyen, Nioi et al. 2009). 




processes, and mechanisms of proteostasis. While it has been reported that basal 
expression of Nrf2 is conserved in older animals, converging evidence suggests that 
Nrf2 activation and Nrf2-regulated protein expression is diminished during aging (Zhou, 
Zhang et al. 2018). Moreover, restoring the activity of Nrf2 through phytochemical 
activation is a promising therapeutic strategy, and Nrf2 activators are currently being 
investigated in clinical trials for their prospective beneficial effects on cellular function 
throughout lifespan.  
 
II. Nrf2 Activators as Therapeutics  
 
Protandim (LifeVantage, Corp.) and PB125 (Pathways Bioscience), commercially 
available plant derived phytochemical compounds known to activate Nrf2, have recently 
been pursued as a strategy for improving cellular function across the lifespan. Recent 
data from The National Institute on Aging Interventions Testing Program (ITP), a multi-
institutional study designed to identify treatments with potential to extend lifespan and 
delay disease/dysfunction in mice, demonstrated that treatment with Protandim 
increased median lifespan of male HET3 mice (Strong, Miller et al. 2016). Additionally, 
our group has shown Protandim protects against oxidative stress induced cell death 
(Donovan, McCord et al. 2012, Reuland, Khademi et al. 2013). Although preliminary 
investigations with Protandim resulted in positive outcomes, the phytochemical cocktail 
PB125, a Nrf2 activator that results in more sustained activation of Nrf2 driven gene 
transcription, bears greater potential for lifespan extension compared to Protandim 




luteolin, and withaferin A, have an extensive history of human consumption, and safety 
of these ingredients has been validated with both human and animal studies (AnadÓN, 
MartÍNez-LarraÑAga et al. 2008, Johnson 2011, Chandrasekhar, Kapoor et al. 2012). 
PB125 is currently being tested in the ITP, however, it is not yet clear if PB125 activates 
mechanisms responsible for protein homeostasis. Therefore, the purpose of the present 
study is to evaluate the effects of treatment with a potent Nrf2 activator, PB125, on rates 
of protein and DNA synthesis in male C57BL6/J mice. 
 
III. Statement of the problem 
The purpose of the present study is to examine the effects of treatment with PB125, a 
potent phytochemical Nrf2 activator, on rates of protein and DNA synthesis in heart, 
liver, and skeletal muscle in C57BL6/J mice aged 15-16 months over the course of a 5-
week feeding study.  
 
IV. Hypotheses 
We hypothesize that mechanisms of proteostasis will be enhanced in subcellular 










CHAPTER II: LITERATURE REVIEW 
 
I.   Oxidative Stress  
 
ROS are constantly formed during cellular metabolism, with endogenous sources of 
ROS being derived from electron leak during enzymatic reactions within the 
mitochondrial electron transport system. Briefly, complex I (NADH-CoQ reductase) and 
complex III (cytochrome C oxidase) are the primary production sites of the free radical 
superoxide anion (O2•‾) (Wong, Dighe et al. 2017). Superoxide anions have the 
potential to directly produce a more reactive radical, the hydroxyl radical (•OH) (O2•- + 
2e- → •OH). • OH is also produced indirectly through the dismutation of superoxide 
anion into hydrogen peroxide (H2O2) by the mitochondrial and cytosolic isoforms of the 
enzyme superoxide dismutase (SOD1/2) in conjunction with its metal co-factor Fe2+ 
(McCord and Fridovich 1968). Additional sources of ROS stem from peroxisomes 
(peroxidases, catalase, xanthine oxidase), lysosomes, and enzymes of the lipid bilayer 
(cyclooxygenases, lipoxygenases, and NADPH oxidases), producing a variety of ROS 
(Giustarini, Dalle-Donne et al. 2009).  
 
Oxidative stress is characterized by a chronic imbalance in ROS production and a 
diminished capacity of antioxidant defenses to eliminate harmful reactive species, and it 
is theorized that oxidative stress-induced damage to macromolecular structures 
contribute to age-associated declines in cellular function (Beckman and Ames 1998). 




lead to the accumulation of ROS (Okoduwa, Umar et al. 2015, Freitas, Boncompagni et 
al. 2016). The data currently available suggest that ROS-induced lipid and protein 
modifications such as peroxidation, carbonylation, nitrosylation and glycation are linked 
to the progression of age-related diseases like cardiovascular disease, liver cirrhosis, 
and sarcopenia. For example, older individuals afflicted by vascular endothelial 
dysfunction possess elevated levels of nitrotyrosine, whereas liver cirrhosis patients 
have increased oxidatively modified lipids (ie. lipid peroxidation) that are associated with 
ROS accumulation (Donato, Eskurza et al. 2007, Reynaert, Gopal et al. 2016). The 
plasma of sarcopenic individuals compared to their non-sarcopenic counterparts have 
higher levels of 4-hydroxynonenal (4-HNE), a modified protein end-product resulting 
from ROS exposure (Bellanti, Romano et al. 2018). It has become apparent that high 
exposure to ROS contributes to the etiology of age-related diseases and causes 
disruptions in redox signaling, likely due to a decreased capacity to eliminate harmful 
ROS (Bakala, Delaval et al. 2003). However, low exposure to oxidants is essential for 
healthy redox signaling and, further, to promote adaptive cellular responses that are 
coordinated by the Nrf2-Keap1-ARE axis (Tebay, Robertson et al. 2015, Egea, 
Fabregat et al. 2017) .  
 
II.  Nrf2-Keap1-ARE Axis  
 
Under normal physiological conditions Nrf2 resides in the cytosol bound to Kelch-like 
ECH-associated protein 1 (Keap1), a cytoskeleton-associated adaptor protein that 
negatively regulates Nrf2 activity (Zhang, Lo et al. 2004). Keap1 serves as a redox 
 
 
sensor of the cellular environment, responding to the presence of Nrf2 activators such 
as oxidants, electrophiles, xenobiotics, and phytochemicals (Wu, McDonald et al. 2014). 
Nrf2 activators interact with key cysteine thiol residues of Keap1, enabling Nrf2 to be 
released from Keap1 and translocate to the nucleus. Once inside the nucleus, Nrf2 is 
able to interact with the Antioxidant/Electrophilic Response Element (ARE), a 
transcriptional element responsible for regulation of gene targets involved in redox 
regulation, phase I-III drug metabolism, iron and heme metabolism, autophagy, and 
proteasome assembly (Dodson, de la Vega et al. 2019). 
 
Nrf2 activity is repressed by Keap1, which is comprised of several domains that 
collectively regulate Nrf2. The double-glycine repeat region (DGR) of dimerized Keap1 
binds the Neh2 domain of Nrf2, driving the formation of Nrf2-Keap1 complex in a “hinge-
and-latch” mechanism. As a result, Nrf2 is kept sequestered in the cytosol by Keap1, 
preventing its nuclear translocation (Itoh, Wakabayashi et al. 1999). It is important to 
note that in non-stressful conditions, Keap1 promotes the degradation of Nrf2 by the 
ubiquitin proteasomal system (UPS). The process of Nrf2 degradation occurs at the 
intervening region (IVR) of Keap1, which recruits RING-box-protein 1 (Rbx1) and binds 
Cullin-3 (Cul3), an E3-ubiquitin ligase that is necessary for Nrf2 ubiquitination and 
subsequent degradation by the 26s proteasome (Zhang, Lo et al. 2004). This 
degradatory mechanism serves as a primary regulator of Nrf2 activity. The IVR is a 
cysteine-rich domain that is sensitive to oxidative modification, primarily by RONS or 




between Nrf2 and Keap1 allows for the rapid detection of changes to redox 
homeostasis in the cytosol and drives gene transcription through the Nrf2-ARE axis.   
 
III.  Nrf2 Activation and Gene Targets of the ARE 
 
Under conditions of oxidative stress, cysteine residues within Keap1 are oxidized 
causing a conformational change in the Nrf2-Keap1 complex that effectively stabilizes 
Nrf2. Lysine residues on Nrf2 become hidden and can no longer be ubiquitinated, 
preventing Nrf2’s degradation and increasing its half-life from roughly 15 to 180 minutes 
(Lewis, Mele et al. 2010). Subsequently, Nrf2 can translocate to the nucleus. Nuclear 
accumulation of Nrf2 results in the formation of heterodimers with small 
masculoaponeurotic fibrosarcoma (MAF) proteins and facilitates binding of Nrf2 to the 
cis promoter region of the ARE. The Nrf2-ARE interaction induces expression of a 
myriad of cytoprotective genes that maintain redox homeostasis. (MacLeod, McMahon 
et al. 2009).  
 
Activation of Nrf2 has been identified as a novel therapeutic strategy primarily because 
of its ability to induce the expression of antioxidant transcriptional programs. An 
important function of Nrf2-related antioxidants is to maintain redox homeostasis via 
adequate regulation of proteins involved in glutathione metabolism (Chen, Liu et al. 
2010). Accordingly, GSH levels are regulated by Nrf2 gene targets GCLM and GCLC, 
which encode for glutamate cysteine ligase, the protein responsible for de novo 




cysteine importer xCT, encoded by the Nrf2 gene target SLC7A11. Nrf2 activation was 
shown to induce expression of xCT mRNA that preceded any increase in GSH protein 
levels (Nishimoto, Koike et al. 2017). With regard to GSH and Nrf2, GPX2 and GPX4 
are gene targets of Nrf2 encoding glutathione peroxidases, which reduce peroxides by 
using GSH as a substrate (Friedmann Angeli, Schneider et al. 2014). Another important 
antioxidant protein downstream of Nrf2 is glutathione reductase (GR), which catalyzes 
the reduction of oxidized glutathione (GSSG) back to GSH. Serving as a crucial redox 
buffer, GSH is present in high concentrations in the cytosol, nucleus, and mitochondria 
(Valko, Leibfritz et al. 2007). The ratio of reduced to oxidized glutathione (GSH:GSSG) 
is an indicator of cellular redox status, and is both directly and indirectly affected by Nrf2 
driven expression of antioxidants. In summary, Nrf2 maintains cellular redox 
homeostasis by inducing gene expression of antioxidant proteins via the ARE.  
 
The transcription factor Nrf2 is also implicated in drug and xenobiotic metabolism. The 
most extensively studied proteins are involved in phase I and II metabolism, which 
reduce toxins and drugs into harmless metabolites. Nrf2 drives expression of aldo-keto 
reductases, aldehyde reductases, and NAD(P)H:quinone oxidoreductase 1 (NQO1), 
another enzyme key to antioxidant defenses (Itoh, Chiba et al. 1997). NQO1 effectively 
combats oxidative stress by detoxifying quinones and preventing redox cycling, a series 
of reactions that propagate free radical production (Gaikwad, Long et al. 2001). Lastly, 
Nrf2 has also been reported to enhance the transcription of a class of membrane 
transporters of the ATP-binding cassette family, functioning to excrete xenobiotics/drugs 




acetaminophen-induced hepatotoxicity, and this was associated with reduced 
expression of Nrf2-regulated drug metabolizing enzymes and antioxidants (Enomoto 
2001). To recapitulate, Nrf2 transcriptionally regulates the expression of a functionally 
diverse set cytoprotective proteins.  
 
IV.  Nrf2 & Proteostasis 
 
Activation of Nrf2-ARE driven gene transcription has been identified as a modulator of 
proteostasis, as Nrf2 coordinates gene transcription of cytoprotective proteins that 
provide resistance to oxidative stress and assuage disruptions in proteostasis. 
Maintaining the proteostatic network requires a functional equilibrium between protein 
synthesis, folding, localization and degradation processes (Diaz-Villanueva, Diaz-Molina 
et al. 2015). Protein turnover, the balance between protein synthesis and degradation 
processes, is essential for protein homeostasis. Sustaining adequate rates of protein 
turnover reduces the potential for damage to macromolecular structures. This is 
important because the enzymatic capacity to repair damaged proteins is limited and 
declines further with age, requiring damaged and/or dysfunctional proteins to be 
degraded to their amino acid constituents (Ryazanov and Nefsky 2002). In concordance 
with this idea, loss of proteostasis has emerged as a hallmark of the aging process, with 
the current body of literature suggesting that the capacity to maintain proteostasis 
declines over lifespan (Basisty, Meyer et al. 2018). While insufficient protein turnover is 
one manifestation, loss of proteostasis is also characterized by altered post-translational 




cellular level. Furthermore, new protein synthesis contributes to establishing a 
functionally stable proteome in the cell and is a cornerstone of maintaining cellular 
function. 
 
Nrf2 signaling may serve as a promoter of protein turnover due to its role in regulating 
the proteasome and autophagy, two critical mechanisms facilitating protein degradation. 
Briefly, the proteasome works in conjunction with the ubiquitin system to degrade short-
lived regulatory proteins and misfolded proteins (Diaz-Villanueva, Diaz-Molina et al. 
2015), and proteasomal assembly requires the expression of proteasome subunit 1 
(PSMA1), proteasome subunit 5 (PSMB5), and proteasome maturation protein 
(POMP), which all contain ARE sequences and are transactivated by Nrf2 (Kwak, 
Wakabayashi et al. 2003, Jang, Wang et al. 2014). Distinct from proteasomal 
degradation is autophagy, a process that eliminates protein aggregates, as well as 
organelles such as the mitochondria and endoplasmic reticulum (Noda and Inagaki 
2015). At the juxtaposition of autophagy and Nrf2 signaling is p62/sequestosome1 
(p62), an adaptor protein that binds ubiquitinated proteins and delivers cargo to the 
autophagosome during autophagic clearance (Lim, Lachenmayer et al. 2015, Liu, Ye et 
al. 2016). p62 links autophagy to the Nrf2-Keap1-ARE axis through its interaction with 
Keap1, as p62 contains a binding motif similar in structure to Nrf2, allowing it to interact 
directly with Keap1 and initiate its degradation (Liu, Ye et al. 2016). Phosphorylation of 
p62 at serine351 increases its binding affinity for Keap1, causing Nrf2’s dissociation and 
subsequent nuclear accumulation (Komatsu, Kurokawa et al. 2010). Interestingly, p62 




loop that promotes Nrf2 activity through the autophagic clearance of Keap1 (Jain, 
Lamark et al. 2010). Investigations using p62 KO mice have revealed that p62 is 
necessary for the expression of NQO1 in oxidative skeletal muscle, indicating that p62 
cooperates with Nrf2 to induce antioxidant expression (Yamada, Iwata et al. 2019). 
Pertaining to Nrf2’s role in activating transcriptional programs of autophagic machinery, 
autophagy related proteins 5 and 7 (ATG) and unc-51-like autophagy activating kinase 
1 and 2 (ULK1/2), are encoded by autophagy genes containing an ARE sequence 
(Pajares, Jiménez-Moreno et al. 2016). Intuitively, these genes are inducible by Nrf2 
activation, placing Nrf2 in a governing role over mechanisms of protein degradation.  
 
Nrf2 functions to coordinate an adaptive response to stressors, contributing to the 
maintenance of protein homeostasis. Importantly, Nrf2 preserves endoplasmic reticulum 
(ER) function by participating in the unfolded protein response (UPR) in concert with 
protein kinase R-like endoplasmic reticulum kinase (PERK) (Cullinan and Diehl 2006, 
Xie, Pariollaud et al. 2015). The ER is considered a key component of the proteostasis 
network, as the ER is the main site of ribosomal translation and post-translational 
folding of proteins. Localized to the ER membrane, PERK is a transdomain kinase that 
mediates signal transduction from the ER lumen to the cytosol and nucleus (Harding, 
Zhang et al. 1999). The ER possesses sensors, like that of PERK, that detect the 
accumulation of unfolded/misfolded proteins and stimulate various effectors to prevent 
proteotoxicity and cell death. Specifically, unfolded proteins unveil  hydrophobic 
residues that are recognized by BIP, a chaperone that is released from PERK’s lumenal 




Simultaneously, PERK activation results in the direct phosphorylation of serine residues 
on eukaryotic initiation factor-alpha (eIF2) and Nrf2, exerting regulation over protein 
synthesis and progression through the cell cycle in response to stress (Ron and Walter 
2007, Chevet, Hetz et al. 2015).  
 
UPR-activated PERK signaling functions to repress global protein translation at the 
onset of ER stress (Cullinan and Diehl 2004). Initiation of the UPR stimulates PERK to 
phosphorylate the translation initiation factor eIF2, causing the inhibition of translation 
initiation (Harding, Zhang et al. 2000). Perturbations in ER homeostasis additionally 
provoke PERK-dependent phosphorylation of Nrf2, causing Nrf2 to be released from 
Keap1 and translocate to the nucleus (Cullinan, Zhang et al. 2003). In agreement with 
this idea, the early stages of oxidative stress promote the PERK-Nrf2 signaling pathway 
to arrest cell cycle via modification of cyclin activity and concentration. Cell cycle 
progression is intricately regulated by a complex network of cyclin dependent kinases 
and their respective cyclin substrates (Malumbres 2014), and are further influenced by 
PERK signaling. At the initial stage of mild oxidative stress, Nrf2 prompts cell cycle 
arrest in G2 by binding to the genetic promoters of p15, p17, and p21, the putative 
stochiometric inhibitors of cyclin D1 activity (Márton, Tihanyi et al. 2018). In contrast, 
prolonged exposure to oxidative stress initiates the degradation of Cyclin D1 in a PERK-
dependent manner, resulting in decreased cyclin D1 protein concentration (Márton, 
Tihanyi et al. 2018). To summarize, the PERK-Nrf2 signaling pathway is an adaptive 
response to oxidative stress that serves to block cell cycle progression by controlling 





In parallel with the aforementioned responses to oxidative stress, cells possess 
additional control mechanisms that modulate cell cycle to promote cell survival. p53, a 
transcription factor that ensures genome integrity by organizing responses to DNA 
damage, is central to the counteraction of oxidative stress (Hiemstra, Niemeijer et al. 
2017). Conditions of prolonged exposure to high concentrations of ROS causes 
oxidation of redox-sensitive cysteines within p53, leading to the expression of gene 
targets that collectively prompt DNA repair, cell cycle arrest, and apoptosis (Fischer, 
Prodeus et al. 2016). Activation of p53 has been identified as a regulator of Nrf2 activity, 
eliciting a diphasic response that is dependent on the degree of oxidative stress (Chen, 
Jiang et al. 2012). On one hand, mild conditions of oxidative stress are associated with 
low levels of p53 and transcriptional activation of p21, a cyclin dependent kinase 
inhibitor that arrests cell cycle at G1 (Cao, Li et al. 2013). The p53-dependent block in 
cell cycle progression allows for the immediate upregulation of Nrf2-dependent 
antioxidant gene transcription, restoration of redox-balance, and subsequent cell cycle 
re-entry. However, when cells are subjected to conditions that invoke cellular damage, 
p53 becomes elevated and the Nrf2 response is suppressed (Chen, Jiang et al. 2012). 
Simultaneous to the suppression of Nrf2-dependent antioxidant response, p53 initiates 
apoptosis, a cell death process that preserves the genome (Luo, Liang et al. 2017). In 
review, p53 regulates Nrf2 to counteract the consequences of ROS accumulation in a 
spatiotemporal manner, as mild concentrations of ROS activates p53 and bolsters the 




induced by excessive ROS causes p53 to block cell cycle progression and induce 
apoptotic cell death (Faraonio, Vergara et al. 2006).  
The diversity of Nrf2’s interactions with the proteostatic network lends significance to the 
central role of Nrf2 in mediating cellular function. Nrf2 is vital for not only the immediate 
restoration of redox-balance, but also the regulation of protein synthesis and 
degradation, the UPR, and several aspects of the cell cycle. With the convoluted nature 
of Nrf2 signaling, investigating the role of Nrf2 in the context of proteostasis requires 
consideration of both protein and DNA synthesis. Accordingly, the present study 
assessed the contribution of new protein synthesis and cellular proliferation to 

















CHAPTER III: METHODS 
 
I.  Animal Care 
51 male C57BL/6J mice aged 15-16 months were purchased from Jackson 
Laboratories. All animals were housed at the Painter Center, home of Colorado State 
University’s (CSU) Laboratory Animal Resources facilities. All procedures were 
approved by the CSU Animal Care and Use Committee, and met or exceeded animal 
housing standards as described in the Animal Welfare Act regulations, the Guide for the 
Care and Use of Laboratory Animals, and the Guide for Care and Use of Agricultural 
Animals in Agricultural Research and Teaching.  
 
II.  Diet Composition – PB125 (Pathways Bioscience) 
Diets were supplemented with PB125, consisting of a combination of three plant-derived 
phytochemicals [Carnosol (Rosemary extract), Withaferin A (Ashwaganda), and 
Luteolin) at two doses in pellet form (Dyets Inc, Bethlehem, PA). The dietary 
composition for each dose is listed as follows: The low dose (100 ppm) dietary 
supplement consisted of Rosemary extract (6.82 x 10-6 mg/g diet), Withaferin A (2.27 x 
10-5 mg/g diet), Luteolin (9.09 x 10-6 mg/g diet). The high dose (300 ppm) consisted of 
Rosemary extract (2.05 x 10-4
 
mg/g diet), Ashwaganda extract (1% withaferin A)(6.82 x 
10-5
 
mg/g diet), Luteolin (2.73 x 10-5
 







III.  Experimental Design  
Mice were randomly assigned to one of three diet groups (n=18/group), consuming 
either CON, LOW, or HIGH doses of PB125 (Figure 1). PB125 was provided ad-libitum 
for the 5-week duration of the study. Mouse body weights and food intake were 
recorded at baseline, then recorded every other day until the completion of the 5-week 
feeding period. Collected data were averaged to obtain mean body weight (Luo, Liang 
et al.) and mean daily food intake (Luo, Liang et al.). 
 
IV.  Deuterium Labeling 
Following a 7-day lead-in on the diet, mice were isotopically labeled with deuterium 
oxide (D2O) to measure protein and DNA synthesis (Figure 1). Mice received a bolus 
intraperitoneal (i.p) injection of 99% D2O (Sigma-Aldrich, St. Louis, MO, USA) in 0.9% 
NaCl relative to 60% of body weight as previously described (Drake, Bruns et al. 2014) 
and 8% D2O was added to the drinking water for the duration of the feeding period to 
maintain D2O enrichment. D2O incorporates into non-labile sites on alanine and 
deoxyribose, providing a strategy to determine fractional synthesis rates (FSR) of 
protein and DNA.   
 
V.  Animal Sacrifice & Tissue Harvest 
12 hours prior to sacrifice, all food was removed from each cage to illicit an overnight 
fast. All animals were anesthetized via i.p. injection with 0.5-1.0 mL of ketamine 
(80mg/kg)/xylazine (20mg/kg) solution. Takedowns were performed at 1, 4, 8, 14, and 




capture protein and DNA synthesis for the full duration of the labeling period (Figure 1). 
Blood was obtained by cardiac venipuncture (approx. 1.0mL), immediately followed by 
excision of heart, liver, and gastrocnemius, and bone marrow was extracted from the 
tibia and femur. All tissues were rinsed in phosphate buffered solution (PBS), dissected 
of connective tissue and weighed on an analytical balance (Denver Instruments) 
accurate within ± 0.1g. Tissues were then flash frozen in liquid nitrogen and stored at -
80°C for future analysis.  
 
VI. Tissue and Analyte Preparation 
 
a. Body Water Derivation and Analysis 
Body water deuterium enrichment was determined from plasma as previously described 
by our lab (Miller, Robinson et al. 2012). Plasma was obtained by centrifugation of 1.0 
ml blood samples at the time of sacrifice. 125 uL of plasma was pipetted into the inner 
well of an o-ring screw cap, and tubes were inverted and incubated on a heat block 
overnight at 80°C. Following overnight incubation, samples were cooled to room 
temperature and 2 uL of 10M NaOH and 20 mL of acetone were added to each sample 
and 0%-20% D2O standards. Samples were then briefly vortexed and allowed to 
incubate overnight at room temperature. The following day, all samples and standards 
were prepared for acetone derivation and subsequent extraction by adding 200 uL of 
hexanes. The organic layer was transferred to gas-chromatography vials with 200 uL 
pipette tips containing Na2SO4. Samples were analyzed via gas-chromatography/mass-




60 were monitored for the acetone derivative and quantified using ChemStation 
software (Agilent Technologies, Santa Clara, CA, USA).  
b. Tissue Fractionation by Differential Centrifugation  
Approximately 40-50 mg of whole skeletal muscle, heart, and liver tissue samples were 
pulverized under liquid nitrogen and used for differential centrifugation to isolate 
mitochondrial enriched (mito), cytosolic (cyto), and mixed (mixed) subcellular protein 
fractions according to our previously published procedures (Miller, Robinson et al. 2013, 
Drake, Bruns et al. 2014). Pulverized tissues were bead homogenized in 1:10 isolation 
buffer (100 mM KCl, 40 mM Tris HCl, 10 mM Tris Base, 5 mM MgCl2, 1 mM EDTA, 1 
mM ATP, pH 7.5) with addition of phosphatase and protease inhibitors (HALT, Thermo 
Scientific, Rockford IL). The initial tissue homogenate was centrifuged at 800g for 10 
min at 4°C. The resulting supernatant was removed and added to a new tube, and the 
pellet was saved as mixed. The supernatant from the previous spin was centrifuged at 
10,000g for 30 min at 4°C, and the resulting pellet was saved as mito. From the 
supernatant, 400 uL was removed and an equal volume (400 uL) of 14% SSA was 
added. The tube incubated on ice for 1hr and labeled as cyto. The remaining volume of 
supernatant from the mito spin was saved for protein quantification. The mito pellet was 
washed with 200 uL buffer #2 (100 mM KCl, 10 mM Tris-HCl, 10 mM Tris Base, 1 mM 
MgSO4, 0.1 mM EDTA, 0.02 mM ATP, and 1.5% BSA, pH 7.4) and centrifuged at 
8000g for 10 min at 4°C. The supernatant was removed, and the pellet was washed a 
second time with 100uL buffer #2 and centrifuged at 6000g for 10 min at 4°C. Following 




incubation, the cyto tube was centrifuged at 16,000g for 10 min at 4°C to yield the Cyto 
protein pellet. The cyto and mixed pellet were washed with 500 uL 100% ethanol, 
centrifuged at 1000g for 4 min at 4°C, and washed with 500 uL ddH2O and centrifuged 
again at 1000g for 4min at 4°C. cyto and Mix wash steps were repeated once. mito, 
cyto, and mixed pellets were solubilized in 250 uL 1M NaOH for 15 min at 50°C and 
hydrolyzed in 6M HCl for 24 hours at 120°C.  
c. Alanine Derivation and Analysis 
Protein was hydrolyzed overnight in 6M HCl at 120°C.  Protein hydrolysates were cation 
exchanged and dried under vacuum according to our previous published procedures 
(Miller, Robinson et al. 2012) Dried hydrolysates were resuspended in 1 mL of 
molecular biology grade water, and approximately 500 uL of sample was used for 
derivation. 500 uL acetonitrile, 50 uL1M K2HPO4, and 20 uL of pentafluorobenzyl 
bromide were added to all samples and standards. Tubes were vortexed and incubated 
on a heating block at 100°C for 1 hour.  Samples were removed from the heating block 
and cooled to room temperature.  Once cooled, 600 uL of ethyl acetate was added to 
each sample and vortexed vigorously to allow for phase separation. Using a Pasteur 
pipette, the organic layer was transferred to GC vials and dried down under N2. After 
drying, samples were reconstituted in 700 uL ethyl acetate, vortexed, and tightly capped 
for analysis on GC/MS. Samples were analyzed by negative chemical ionization in 
selective ion monitoring mode. A DB225 gas chromatograph column was used to 
separate amino acid derivatives. Starting temperature was 100°C and increased to 
220°C at a rate of 10°C per minute with helium as the carrier gas and methane as the 




pentafluorobenzyl-N,N-di(pentafluorobenzyl)alaninate derivative, and quantified using 
ChemStation software (Agilent Technologies, Santa Clara, CA, USA). The mass-to-
charge ratios represented the primary daughter ions that included all of the original 
hydrocarbon bonds from the given amino acid. 2H enrichment was calculated as the 
M+1 mass isotopomer divided by the sum of the M+1 and M+0 mass isotopomers 
(Hellerstein & Neese, 1999). The newly synthesized fraction of proteins was calculated 
by dividing the deuterium enrichment of alanine from protein by the precursor 
enrichment from body water (plasma). The precursor enrichment was determined from 
the enrichment of deuterium in body water and adjusted using mass isotopomer 
distribution analysis (MIDA) to determine alanine enrichment (Hellerstein & Neese, 
1999).  Protein synthetic rates were calculated by dividing fraction new by time and 
expressed as fractional synthesis rates (%FSR/day). 
 
d. DNA Extraction and Derivation 
 
DNA was isolated from whole tissue and bone marrow (QIAamp DNA mini kit, Qiagen, 
Valencia, CA, USA) and hydrolyzed overnight at 37°C with nuclease S1 and potato acid 
phosphatase.  Next, 80uL of glacial acetic acid and 100 uL pentafluorobenzyl 
hydroxylamine solution were added to sample hydrolysates and standards (1-30 ug/ml 
range deoxyribose) and incubated on a heating block for 30 min at 100°C.  Following 
incubation, samples were cooled to room temperature and then reacted with 1ml acetic 
anhydride and 100 uL n-methylimidazole for 15-20 minutes. After the reaction reached 




added to each tube and vortexed to induce phase separation. The bottom organic layer 
was extracted and expelled into a new tube containing granular anhydrous Na2SO4. An 
additional 750uL methylene chloride was added to samples, and extraction steps were 
repeated. Extraction was then transferred from tubes containing Na2SO4 to GC vials. 
GC vials were vacuum dried for one hour and reconstituted in 70uL ethyl acetate. Ethyl 
acetate was transferred to tapered GC vial insert and placed back into GC vials, which 
were tightly capped for GC/MS analysis. Samples were then analyzed by GC/MS with a 
DB-17MS column using negative chemical ionization with helium as the carrier gas and 
methane as the reagent. The pentafluorobenzyl triacetyl derivative of purine dR was 
monitored for the fractional molar isotope abundances at m/z 435 and 436, and 
quantified using ChemStation software (Agilent Technologies, Santa Clara, CA, USA).  
DNA fraction new was calculated in comparison to bone marrow, which represents a 
fully turned over population of cells (Miller et al., 2012). DNA synthesis rates were 
calculated by dividing DNA fraction new by time and expressed as fractional synthesis 
rates (FSR%/day). The protein FSR was then expressed relative to the DNA FSR to 
obtain the PRO:DNA synthesis ratio.  
 
VII. Immunoblotting & Band Detection  
Heart, liver, and skeletal muscle were homogenized using lysis buffer composed of 50 
mM HEPES, 12 mM Na4P207, 100 mM NaF, 10 mM EDTA, 400μL of Protease and 
Phosphatase Inhibitors, and 5 mL of 10%Triton. Protein (30 μg) was loaded onto a 8-
16% SDS-PAGE gel, run at 200V for one hour and transferred to PVDF membranes.   




(Abcam-ab180650), thioredoxin reductase 1 (Novus-6925S), and glutathione reductase 
(Abcam-16801) diluted to 1g/mL and placed on a plate shaker overnight at 4C. After 
washing with TBST, the membranes were incubated with horse-radish peroxidase-
conjugated anti-rabbit secondary antibodies (Cell Signaling-7074P2) and TBST washing 
was repeated. Protein bands were imaged on a FluorChem E chemiluminescence 
imager (Protein Simple) and quantified using AlphaView SA software.  
VIII. Protein Aggregation   
Skeletal muscle and liver protein aggregation were determined using the Proteostat 
protein aggregation assay, fluorescence-based assay kit (Enzo Life Sciences). Protein 
was added to 1X diluted Proteostat assay buffer. Once in solution, 98 μL of protein 
(10μg/mL) was loaded onto a 96-well plate with 2 μL of 1X diluted Proteostat detection 
reagent, then incubated in the dark at room temperature for 15 minutes. The microplate 
was then read with a fluorescence microplate reader at an excitation setting of 550 nm 
and an emission filter of 600 nm. The resulting signal was compared against a standard 
curve of aggregated IgG generated from Proteostat standards and normalized to total 
protein.  
IX. Statistics and Data Analyses 
Statistical analyses were performed using Prism Graphpad Version 8 (La Jolla, CA). All 
values are presented as means  SEM. Changes in protein turnover over time were 
determined by a two-way ANOVA as treatment by time, while individual time points 
(protein synthesis, western blots, and protein aggregation) were analyzed using a one-
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Figure 1. Timeline of experimental design. Mice received a bolus interperitoneal 
injection of 99% D2O following a week lead in on either CON, LOW, or HIGH 
PB125 supplemented diets. 8% D2O was supplied to the mice ad-libitum for the 
duration of the feeding period to maintain the enrichment of D2O in the body 
water. Mice were sacrificed and tissues were harvested after 1, 4, 8, 14, and 34 




















































Figure 2. Average body weight (g) (A). Average daily food intake (g)/day (B) for 
mice treated with CON, LOW, or HIGH doses of PB125. * denotes significant 
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Figure 3. Protein fractional synthesis rates (FSR) in mito, cyto, and mixed 
subcellular fractions during 5 weeks of CON, LOW, or HIGH doses of PB125 
supplementation in skeletal muscle (A), heart (B), and liver (C). Data are 
reported on 1, 4, 8, 14, and 34 days of deuterium labeling.  



























































































































Figure 4. DNA fractional synthesis rates (FSR %/day) in skeletal muscle (A), 































































































Figure 5. Synthetic ratios of PRO:DNA (FSR %/day) mito, cyto, and mixed 
subcellular fractions of skeletal muscle (A), heart (B), and liver (C) at two doses 






















































































































































































































































































































Figure 6. Content of antioxidant proteins Glutathione-S-Transferase (GST), 
Thioredoxin Reductase 1 (Trxr1), and Glutathione Reductase (GR) in skeletal muscle 



































































































I. Body Weight and Food Intake  
 
There were no significant differences in body weight between treatment groups, 
however, all groups displayed a decrease in body weight pre to post 5-week feeding 
trial (Figure 2A). However, the weekly average body weight showed no statistical 
difference between each group over time. There were also no significant differences in 
average daily food intake between treatment groups (Figure 2B). Subjectively speaking, 
the mice tolerated both doses of PB125 supplemented diet, with no signs of 
gastrointestinal distress or abnormal behavior.  
 
II. Protein and DNA Synthesis 
 
Figure 3 demonstrates protein FSR (1/day) in skeletal muscle, heart, and liver tissue. 
There were no significant differences between treatment groups in protein FSR of mito, 
cyto, or mixed subcellular fractions of any tissue. To determine the influence of PB125 
supplementation on mechanisms of proteostasis, protein:DNA (PRO:DNA) synthetic 
ratios (FSR %/day) were calculated for skeletal muscle, heart, and liver tissues at time 
27 8
Figure 7. Quantification of protein aggregation in liver and skeletal muscle after 




















Skeletal Muscle Protein Aggregation 
 
 
point 34 (days), which are displayed in Figure 5. Although there were no significant 
differences in PRO:DNA ratios, all tissues displayed similar trends between treatment 
groups in mito, cyto, and mixed fractions (Figure 5). Despite the lack of statistical 
significance, skeletal muscle (Figure 5A) had the highest PRO:DNA in the HIGH dose 
group, which may be partially explained by the insignificant trend toward reduced 
skeletal muscle DNA synthesis (Figure 4A). PRO:DNA ratios were not statistically 
different in heart and liver (Figure 5B-C). No significant differences were found in DNA 
FSR in any tissues (Figure 4A-C). 
 
III. Protein Content and Aggregation  
 
There were no significant differences in antioxidant protein content between PB125 
treated groups in skeletal muscle, heart, or liver tissue at 34 days (Figure 6). To further 
investigate if PB125 improved mechanisms of proteostasis, we measured protein 
aggregation in skeletal muscle and liver tissue (Figure 7). There were no significant 










CHAPTER V: DISCUSSION 
I. Principal Outcomes 
In the present study, protein and DNA synthesis rates were measured for the purpose of 
interrogating mechanisms of proteostatic maintenance in mitochondrial, cytosolic, and 
mixed subcellular fractions of skeletal muscle, heart, and liver tissue of 15-16 month old 
mice that were consuming a diet containing CON, LOW, or HIGH doses of the 
phytochemical Nrf2 activator PB125. We hypothesized that treatment with a PB125-
supplemented diet (LOW and HIGH doses) would improve protein homeostasis, as 
indicated by an increased PRO:DNA synthesis ratio. Additionally, we hypothesized that 
mice consuming PB125 in their diet would have increased expression of antioxidant 
proteins and reduced levels of protein aggregation relative to the control group. Our 
findings show that protein and DNA synthesis rates in heart, liver, and skeletal muscle 
were unaffected by supplementation with PB125; and Nrf2-regulated protein expression 
of glutathione-S-transferase, thioredoxin reductase 1, and glutathione reductase were 
not significantly different between treatment groups in any tissues. Protein aggregation 
was measured in skeletal muscle and liver, with our results suggesting that PB125 
supplementation did not affect protein aggregation. Collectively, we anticipated 
enhanced proteostasis outcomes in mice treated with either LOW or HIGH doses of 
PB125 compared to the control group. The principal outcome from this study is that 
protein homeostasis in PB125 treated mice is not statistically different than CON in 






A key mechanism of protein homeostasis is the synthesis of new protein. As such, the 
primary goal of this study was to determine if treatment with the phytochemical-based 
Nrf2 activator, PB125, could improve proteostatic maintenance in vivo. To assess the 
role of PB125 in modulating proteostasis, the ratio of newly synthesized protein to DNA 
(PRO:DNA) was measured in skeletal muscle, heart, and liver tissue. Measuring rates 
of protein and DNA synthesis simultaneously facilitates evaluation of the contribution of 
cell proliferation to the measured rates of protein synthesis. Providing further context, a 
greater PRO:DNA ratio indicates that more of the protein synthetic resources are being 
allocated to repair and maintenance of existing cells (somatic maintenance) at the 
expense of cellular growth (proliferation). In agreement with this, our lab has previously 
demonstrated that targeting Nrf2 activation improves proteostasis during exposure to 
oxidative stress in vitro. Myoblasts co-cultured with the Nrf2 activator Protandim and 
H2O2  had improved mechanisms of proteostatic maintenance when faced with an 
oxidative challenge, as indicated by an increased PRO:DNA synthetic ratio (Bruns, 
Ehrlicher et al. 2018). Additionally, this study reports in vivo skeletal muscle data from 
rats treated with Protandim (600ppm) and allowed to run on exercise wheel for 6 weeks. 
Protandim was demonstrated to enhance mitochondrial proteostasis in the plantaris 
muscle, reflected by an increased PRO:DNA synthetic ratio only in the Protandim 
treated rats. However, in the present in vivo study using PB125, there were no 
significant differences in protein synthesis or in the accumulation of aggregated 
proteins, indicating that treatment with the Nrf2 activator had no apparent effect on in 




support the detection of differences in PRO:DNA ratios at individual time points due to 
small sample sizes (n=3-4/group/timepoint). Rather, the experimental design was 
selected to determine long-term differences in synthesis rates of proteins with slow vs. 
rapid turnover, providing an advantageous approach to identify statistical differences in 
protein and DNA synthesis rates (k=1/day) over time. This data is generated by 
performing a one-phase non-linear curve fit using all time points throughout the five-
week labeling period (Pettit, Jonsson et al. 2017). While we are not able to confirm the 
hypothesis that treatment with LOW and HIGH doses of PB125 results in increased 
PRO:DNA ratios relative to CON, a number of factors likely influenced our outcomes 
and require consideration upon interpreting our data; and as such, will be the focus of 
the forthcoming discussion.  
 
Two primary factors may have limited our ability to detect differences in proteostatic 
maintenance and are, therefore, worthy of discussion. First, although the mice used 
were approaching old age, they were not otherwise “stressed.” Given that Nrf2 
activation is indispensable for coordinating adaptive responses to oxidative and other 
stresses (Leung, Kwong et al. 2003), selecting a model subjected to stress might have 
revealed the true potential of PB125 to modulate proteostasis. Interrupting Nrf2 activity 
through genetic knockout offers a convenient model for understanding the biological 
consequences of dysfunctional Nrf2 signaling. Indeed, Nrf2 knockout severely affects 
the balance between ROS and antioxidants, causing increased incidence of pathology 





In the context of aging and disrupted Nrf2 activity, 24-month old mice were used in a 
study by Ahn and colleagues to investigate the role of Nrf2 deficiency on skeletal 
muscle quality and function. They found that Nrf2 deficient old mice have significantly 
decreased muscle mass and contractile dysfunction compared to their age-matched 
wild type counterparts (Ahn, Pharaoh et al. 2018). Another key parameter from this 
study is the measurement of mitochondrial function in permeabilized red gastrocnemius 
fibers of the old Nrf2 deficient mice, with results showing elevated ROS production, 
reduced complex I respiration, and an associated increase in the ratio of NAD+ /NADH 
(Ahn, Pharaoh et al. 2018). In an independent study utilizing an aged Nrf2 knockout 
model, investigators revealed that the skeletal muscle of old mice lacking Nrf2 are 
deplete of antioxidants and GSH, which is associated with ROS accumulation and 
apoptosis. However, Nrf2 knockout in young animals did not affect antioxidant protein 
expression or ROS production, suggesting that the loss of Nrf2 in the absence of a 
stressed setting causes minimal disruptions to redox status (Miller, Gounder et al. 
2012).  
 
The necessity of Nrf2 activation was assessed in the presence and absence of stress 
by Li and colleagues by knocking out Nrf2 and evaluating cardiac function in response 
to hemodynamic stress. Nrf2 knockout did not result in any structural or functional 
changes to cardiac tissues in the absence of stress; however, when hemodynamic 
stress was induced by transverse aortic constriction there was significant myocardial 
fibrosis and apoptosis and increased levels of 4-HNE, a marker of oxidative damage (Li, 




either phytochemical Nrf2 activation or Nrf2 overexpression have revealed that targeting 
Nrf2 activation confers stress resistance and cytoprotection (He, Kan et al. 2009, Liang, 
Li et al. 2017, Chen, Fan et al. 2019). Our group has confirmed this notion in vitro with 
human coronary artery endothelial cells. Specifically, these cells were treated with 
Protandim prior to an oxidative challenge and resulted in increased resistance to H2O2  
compared to vehicle treated cells, and this resistance was indicated by significantly 
decreased nuclear apoptosis (Donovan, McCord et al. 2012). In a model using an 
adeno-associated virus to overexpress Nrf2, ROS levels were reduced in vitro, and in 
vivo mouse data with Nrf2 overexpression demonstrated a protective effect against 
acetaminophen-induced hepatotoxicity (Liang, Woodard et al. 2017). Furthermore, the 
available literature suggests that Nrf2 activation is indispensable for cellular function 
during aging and conditions of oxidative stress. 
 
The second consideration that should be taken when interpreting our findings is the 
bioavailability of the active ingredients comprising PB125: carnosol, luteolin, and 
withaferin A. Briefly, these phytochemicals are metabolized in the intestines and liver 
into various metabolites. In this context, clarifying the concentration of metabolites as 
well as their distribution across tissues and organs is important for interpreting their 
biological effects in vivo. As such, a study conducted by Vaquero et al. employed oral 
administration of rosemary extract, the source of carnosol, to Zucker rats to assess 
metabolites and their respective concentrations in the small and large intestines, the 
liver, and plasma via LC-MS/MS analyses. Carnosol was rapidly detected in the 




study focused on characterizing the pharmokinetics of luteolin, Chen and colleagues 
used HPLC-MS to identify the concentration of luteolin in the plasma of rats and found 
that the plasma concentration of luteolin peaked 1 hour after oral administration, and 
was detectable for a total of 10 hours in the plasma (Chen, Liu et al. 2010). A recent 
study examining the bioavailability of luteolin determined that luteolin is efficiently 
absorbed in the intestine and then metabolized by the liver. However, luteolin is rapidly 
metabolized by enterocytes and hepatocytes into circulating metabolites, with luteolin-
3’-O-ß-D-glucuronide being the most abundant metabolite across tissues. Thus, the 
resulting metabolites from oral luteolin administration contribute to its overall 
bioavailability (Deng, Gao et al. 2017). Lastly, it has been shown that withaferin A is 
detectable in the plasma of mice shortly after oral administration (Patil, Gautam et al. 
2013). Though these investigations used higher doses of carnosol, luteolin, and 
withaferin A than the dosages in PB125, they provide useful insight to the absorption, 
distribution, metabolism, and excretion (ADME) of PB125’s active ingredients. When 
taken collectively, the ADME data from these investigations indicate that carnosol, 
luteolin and withaferin A and their metabolic derivatives reach biologically relevant 
concentrations in the plasma and tissues when orally administered. However, the 
pharmokinetics of these compounds were not measured in the present study. Moreover, 
understanding the parameters surrounding the safety and bioavailability of PB125 
allows for increased precision when developing phytochemical compounds and testing 
their applicability as therapeutic interventions.  
 




To summarize, the present study is the first to characterize mechanisms of proteostatic 
maintenance following o treatment with PB125, a potent phytochemical Nrf2 activator, in 
15-16-month-old C57BL6/J mice. The mice appeared to tolerate the PB125-
supplemented diets well, providing further confirmation of PB125’s safety when 
administered orally. The protein and DNA synthesis data do not confirm our group’s 
previous studies showing that treatment with phytochemical Nrf2 activators cause 
marked improvements in proteostasis during an oxidative challenge. However, the use 
of an “unstressed” animal model in the present study may have limited our ability to 
detect significant differences in proteostasis outcomes. Future investigations are 
therefore necessary to discern whether treatment with PB125 can improve proteostasis 
in vivo. Preferably, future research would use experimental conditions that create robust 
impairments in protein homeostasis, such as in aged mice or an inducible model of 
stress in a specific tissue of interest. Additionally, future experiments should include 
both male and female animals, as data from the ITP suggest that the beneficial effects 
of phytochemical Nrf2 activation are sex specific, and this interaction is yet to be 
completely understood. For this reason, our group is currently examining the effects of 
long-term daily dosing with PB125 in both male and female Dunkin Hartley guinea pigs, 
an animal model utilized to study the progression of knee osteoarthritis and sarcopenia. 
Therefore, with careful consideration of our current findings and potential limitations 
discussed, future investigations will continue to focus on the potential of phytochemical 
Nrf2 activation as a promising therapeutic strategy for improving cellular function and 
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